156 related articles for article (PubMed ID: 16638573)
1. Effect of anti-tumor ether lipids on ordered domains in model membranes.
Heczková B; Slotte JP
FEBS Lett; 2006 May; 580(10):2471-6. PubMed ID: 16638573
[TBL] [Abstract][Full Text] [Related]
2. Membrane peroxidative damage enhancement by the ether lipid class of antineoplastic agents.
Wagner BA; Buettner GR; Burns CP
Cancer Res; 1992 Nov; 52(21):6045-51. PubMed ID: 1394229
[TBL] [Abstract][Full Text] [Related]
3. Edelfosine is incorporated into rafts and alters their organization.
Ausili A; Torrecillas A; Aranda FJ; Mollinedo F; Gajate C; Corbalán-García S; de Godos A; Gómez-Fernández JC
J Phys Chem B; 2008 Sep; 112(37):11643-54. PubMed ID: 18712919
[TBL] [Abstract][Full Text] [Related]
4. Effects of the anti-neoplastic agent ET-18-OCH3 and some analogs on the biophysical properties of model membranes.
Torrecillas A; Aroca-Aguilar JD; Aranda FJ; Gajate C; Mollinedo F; Corbalán-García S; de Godos A; Gómez-Fernández JC
Int J Pharm; 2006 Aug; 318(1-2):28-40. PubMed ID: 16624506
[TBL] [Abstract][Full Text] [Related]
5. Edelfosine and miltefosine effects on lipid raft properties: membrane biophysics in cell death by antitumor lipids.
Castro BM; Fedorov A; Hornillos V; Delgado J; Acuña AU; Mollinedo F; Prieto M
J Phys Chem B; 2013 Jul; 117(26):7929-40. PubMed ID: 23738749
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of K562 and HL-60 cells to edelfosine, an ether lipid drug, correlates with production of reactive oxygen species.
Wagner BA; Buettner GR; Oberley LW; Burns CP
Cancer Res; 1998 Jul; 58(13):2809-16. PubMed ID: 9661895
[TBL] [Abstract][Full Text] [Related]
7. Tumor cell kinetics following antineoplastic ether phospholipid treatment.
Principe P; Sidoti C; Braquet P
Cancer Res; 1992 May; 52(9):2509-15. PubMed ID: 1568220
[TBL] [Abstract][Full Text] [Related]
8. Exclusion of a transmembrane-type peptide from ordered-lipid domains (rafts) detected by fluorescence quenching: extension of quenching analysis to account for the effects of domain size and domain boundaries.
Fastenberg ME; Shogomori H; Xu X; Brown DA; London E
Biochemistry; 2003 Oct; 42(42):12376-90. PubMed ID: 14567699
[TBL] [Abstract][Full Text] [Related]
9. Ether lipid 1-O-octadecyl-2-O-methyl-3-glycero-phosphocholine inhibits cell-cell adhesion through translocation and clustering of E-cadherin and episialin in membrane microdomains.
Van Slambrouck S; Hilkens J; Steelant WF
Oncol Rep; 2008 Jan; 19(1):123-8. PubMed ID: 18097585
[TBL] [Abstract][Full Text] [Related]
10. Induction of resistance in the human leukemia cell line HL60 towards hexadecylphosphocholine and other ether phospholipid analogues.
Berkovic D; Haase D; Hiddemann W; Fleer EA
J Exp Ther Oncol; 1996 Nov; 1(6):368-75. PubMed ID: 9414427
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and growth inhibitory properties of glycosides of 1-O-hexadecyl-2-O-methyl-sn-glycerol, analogs of the antitumor ether lipid ET-18-OCH3 (edelfosine).
Marino-Albernas JR; Bittman R; Peters A; Mayhew E
J Med Chem; 1996 Aug; 39(17):3241-7. PubMed ID: 8765506
[TBL] [Abstract][Full Text] [Related]
12. In vitro antiproliferative activity of combinations of ether lipid analogues and DNA-interactive agents against human tumor cells.
Noseda A; Berens ME; White JG; Modest EJ
Cancer Res; 1988 Apr; 48(7):1788-91. PubMed ID: 3349458
[TBL] [Abstract][Full Text] [Related]
13. Anticancer Agent Edelfosine Exhibits a High Affinity for Cholesterol and Disorganizes Liquid-Ordered Membrane Structures.
Ausili A; Martínez-Valera P; Torrecillas A; Gómez-Murcia V; de Godos AM; Corbalán-García S; Teruel JA; Gómez Fernández JC
Langmuir; 2018 Jul; 34(28):8333-8346. PubMed ID: 29924618
[TBL] [Abstract][Full Text] [Related]
14. Effect of edelfosine on tumor and normal cells model membranes--a comparative study.
Hac-Wydro K; Dynarowicz-Łatka P
Colloids Surf B Biointerfaces; 2010 Mar; 76(1):366-9. PubMed ID: 19896813
[TBL] [Abstract][Full Text] [Related]
15. Surface-active properties of the antitumour ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (edelfosine).
Busto JV; Sot J; Goñi FM; Mollinedo F; Alonso A
Biochim Biophys Acta; 2007 Jul; 1768(7):1855-60. PubMed ID: 17543274
[TBL] [Abstract][Full Text] [Related]
16. Searching for the role of membrane sphingolipids in selectivity of antitumor ether lipid-edelfosine.
Hac-Wydro K; Dynarowicz-Łatka P
Colloids Surf B Biointerfaces; 2010 Dec; 81(2):492-7. PubMed ID: 20719476
[TBL] [Abstract][Full Text] [Related]
17. Novel anti-inflammatory action of edelfosine lacking toxicity with protective effect in experimental colitis.
Mollinedo F; Gajate C; Morales AI; del Canto-Jañez E; Justies N; Collía F; Rivas JV; Modolell M; Iglesias A
J Pharmacol Exp Ther; 2009 May; 329(2):439-49. PubMed ID: 19244550
[TBL] [Abstract][Full Text] [Related]
18. Lipid rafts and metabolic energy differentially determine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cells.
Vink SR; van der Luit AH; Klarenbeek JB; Verheij M; van Blitterswijk WJ
Biochem Pharmacol; 2007 Nov; 74(10):1456-65. PubMed ID: 17803969
[TBL] [Abstract][Full Text] [Related]
19. Dual role of hexadecylphosphocholine (miltefosine) in thermosensitive liposomes: active ingredient and mediator of drug release.
Lindner LH; Hossann M; Vogeser M; Teichert N; Wachholz K; Eibl H; Hiddemann W; Issels RD
J Control Release; 2008 Jan; 125(2):112-20. PubMed ID: 18022271
[TBL] [Abstract][Full Text] [Related]
20. Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: development and in vitro characterization.
Estella-Hermoso de Mendoza A; Rayo M; Mollinedo F; Blanco-Prieto MJ
Eur J Pharm Biopharm; 2008 Feb; 68(2):207-13. PubMed ID: 17707618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
